Pharmaceutical

Sable Therapeutics and Columbia sign deal on obesity treatments

Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.

Aug 13, 2024 - 04:00
Sable Therapeutics and Columbia sign deal on obesity treatments
Sable Therapeutics has signed an agreement with Columbia University to develop new polycation nanomedicines aimed at treating obesity.
Read the original article

Tags:

Previous Article

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Next Article

ARS Pharmaceuticals’ anaphylaxis nasal spray gains FDA approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages

STAT+: In large trial, Guardant Health’s blood test det...

Mar 13, 2024

Hoth and Aronnax partner for HT-KIT cancer therapy development

Hoth and Aronnax partner for HT-KIT cancer therapy deve...

Aug 17, 2024

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Ginkgo buys StrideBio’s AAV discovery and engineering p...

Apr 6, 2023